Example searches

ENZ Enzo Biochem, Inc.

Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Company profile

Ticker
ENZ
Exchange
NYSE
Website
www.enzo.com
CEO
Elazar Rabbani
Employees
Incorporated in
New York
Location
New York
Fiscal year end
Jul 31
Sector
Health Services > Biotechnology
Industry (SEC)
Services - Medical Laboratories
Quest Diagnostics • Laboratory Corp of America • RadNet • Guardant Health • Genomic Health • Invitae • Natera • Centogene B.V. • American Shared Hospital Services • Personalis ...
SEC CIK
0000316253
Corporate docs
IRS number
132866202

ENZ stock data

(
)

Calendar

9 Jun 20
12 Jul 20
31 Jul 20

News

Company financial data Financial data

Chart ENZ financial data
Quarter (USD) Apr 20 Jan 20 Oct 19 Jul 19
Revenue 16.9M 19.38M 20.21M 20.92M
Net income -9.86M -7.69M -7.65M -5.39M
Diluted EPS -0.21 -0.16 -0.16 -0.12
Net profit margin -58.33% -39.66% -37.85% -25.76%
Operating income -9.72M -8.01M -8.2M -5.67M
Net change in cash 2.91M -5.39M -3.25M -3.91M
Cash on hand 54.41M 51.5M 56.89M 60.15M
Cost of revenue 12.48M 13.58M 14.52M 14.58M
Annual (USD) Jul 19 Jul 18 Jul 17 Jul 16
Revenue 81.17M 101.01M 105.09M 102.77M
Net income 2.49M -10.32M -2.5M 45.29M
Diluted EPS 0.05 -0.22 -0.05 0.97
Net profit margin 3.07% -10.22% -2.38% 44.06%
Operating income 1.73M -12.16M -3.15M 46.85M
Net change in cash 105K -4.13M -3.61M 49.67M
Cash on hand 60.15M 60.04M 64.17M 67.78M
Cost of revenue 57.92M 60.39M 59.48M 42.86M

Financial data from company earnings reports

Recent insider trades

ENZ insider ownership history Insider history
Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
23 Apr 20 Perlysky Dov Stock Option (to acquire Common Stock) Common Stock Grant Aquire A No 2.65 83,333 220.83K 258,679
23 Apr 20 Fischer Rebecca J. Stock Option (to acquire Common Stock) Common Stock Grant Aquire A No 2.65 83,333 220.83K 83,333
23 Apr 20 Clemens Peter J Iv Stock Option (to acquire Common Stock) Common Stock Grant Aquire A No 2.65 83,333 220.83K 98,333
23 Apr 20 Clemens Peter J Iv Stock Option (to acquire Common Stock) Common Stock Grant Aquire A No 2.65 83,333 220.83K 83,333
23 Apr 20 Blank Fabian Stock Option (to acquire Common Stock) Common Stock Grant Aquire A No 2.65 83,333 220.83K 83,333
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2020

ENZ institutional ownership history Ownership history
60.6% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 77 82 -6.1%
Opened positions 8 5 +60.0%
Closed positions 13 12 +8.3%
Increased positions 21 26 -19.2%
Reduced positions 28 23 +21.7%
13F shares
 Current Prev Q Change
Total value 113.15M 112.19M +0.9%
Total shares 28.83M 32.22M -10.5%
Total puts 17.1K 0 NEW
Total calls 27K 0 NEW
Total put/call ratio 0.6 – –
Largest owners
 Shares Value Change
Harbert Fund Advisors 5.62M $14.22M 0.0%
Evermore Global Advisors 4.01M $10.14M 0.0%
BLK BlackRock 3.65M $9.23M -1.3%
Renaissance Technologies 3.31M $8.38M -1.2%
Vanguard 2.26M $5.71M +4.6%
Dimensional Fund Advisors 2.07M $5.23M -2.9%
Wellington Management 1.69M $4.27M -52.8%
Ariel Investments 870.08K $2.2M -9.9%
STT State Street 758.63K $1.92M -4.7%
Geode Capital Management 559.74K $1.42M +8.9%
Largest transactions
 Shares Bought/sold Change
Wellington Management 1.69M -1.89M -52.8%
Fondren Management 0 -727K EXIT
Oxford Asset Management 0 -191.85K EXIT
MS Morgan Stanley 7.19K -134.54K -94.9%
Two Sigma Investments 0 -116.19K EXIT
Vanguard 2.26M +99.91K +4.6%
Ariel Investments 870.08K -95.51K -9.9%
Millennium Management 127.92K +89.67K +234.4%
Squarepoint Ops 0 -73.44K EXIT
Dimensional Fund Advisors 2.07M -61.84K -2.9%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
WaferGen Bio-systems
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Additionally, affiliated, aforementioned, agency, Aid, antibody, Article, assistance, augmenting, Authorization, back, began, broader, cancelation, cancellation, cancelled, chain, CHF, CMS, committed, comply, context, coordinated, Corona, covenant, creditor, curtailing, deemed, distancing, documentation, documented, driven, duration, eased, economy, eligibility, eligible, emergency, employee, en, EUA, evolving, exacerbate, expenditure, explained, failure, FDA, forecasted, forgiven, half, hamper, healthy, HHS, highly, Human, inter, invoiced, iv, knowledge, Krise, LDT, lessen, light, long, lost, magnitude, media, mentioned, moderated, national, noncompliance, outbreak, pandemic, passed, Paycheck, payroll, penalty, persist, personnel, power, PPP, prepaid, prolonged, publicly, purported, purpose, put, ratio, recessionary, recoverable, recovery, refinance, regulatory, remote, repaid, repay, replace, reprieve, rest, restore, safe, salary, satisfy, SBA, scope, sector, sequestration, serological, short, show, small, social, specimen, speed, spent, spread, strain, sum, supply, suspended, Suspending, suspension, Switzerland, target, technical, temporarily, theinter, thereunder, Trademark, tranche, travel, twenty, uncollateralized, unconditional, undetermined, unprecedented, unrecouped, usage, verified, voluntarily, waiver, week, withheld, workforce, worse
Removed: argument, final, gain, heard, international, monitored, procedural, PTAB, regularly, remand, reverse, twointer
From filing 10-Q 2020 Q3

Financial reports

View all
10-Q
2020 Q3
Quarterly report
9 Jun 20
10-Q
2020 Q2
Quarterly report
6 Mar 20
10-Q
2019 Q1
Quarterly report
10 Dec 19
10-K/A
2019 FY
Annual report (amended)
26 Nov 19
10-K
2019 FY
Annual report
15 Oct 19
10-Q
2019 Q3
Quarterly report
10 Jun 19
10-Q
2019 Q2
Quarterly report
11 Mar 19
10-Q
2019 Q1
Quarterly report
10 Dec 18
10-K
2018 FY
Annual report
15 Oct 18
10-Q
2018 Q3
Quarterly report
11 Jun 18

Current reports

View all
8-K
Regulation FD Disclosure
25 Jun 20
8-K
Enzo Biochem Reports Third Quarter 2020 Financial Results
8 Jun 20
8-K
Entry into a Material Definitive Agreement
24 Apr 20
8-K/A
Other Events
14 Apr 20
8-K
Regulation FD Disclosure
9 Apr 20
8-K
Enzo Biochem Reports Fiscal Second Quarter Results
5 Mar 20
8-K
Amendments to Articles of Incorporation or Bylaws
2 Mar 20
8-K
Enzo Biochem Announces Preliminary Results of Voting at Annual Shareholder Meeting
25 Feb 20
8-K
Enzo Biochem Reports Publication of Study Detailing Promising Activity of Drug Candidate SK1-I in a Model of Lupus
19 Feb 20
8-K
Other Events
18 Feb 20

Registration and prospectus

View all
S-8
Registration of securities for employees
6 Mar 20
S-8
Registration of securities for employees
13 Aug 18
S-3
Shelf registration
1 Sep 17
S-3/A
Shelf registration (amended)
28 Oct 16
S-3
Shelf registration
1 Sep 16
424B5
Prospectus supplement for primary offering
31 Dec 14
S-8
Registration of securities for employees
25 Jun 14
S-3
Shelf registration
1 Aug 13
424B5
Prospectus supplement for primary offering
28 Mar 13
424B5
Prospectus supplement for primary offering
29 Jun 12

Proxies

View all
DFAN14A
Additional proxy materials by non-management
20 Feb 20
DFAN14A
Additional proxy materials by non-management
19 Feb 20
DEFA14A
Additional proxy soliciting materials
18 Feb 20
DEFA14A
Additional proxy soliciting materials
14 Feb 20
PRER14A
Preliminary revised proxy
11 Feb 20
DFRN14A
Revised proxy by non-management
11 Feb 20
DEFA14A
Additional proxy soliciting materials
7 Feb 20
DFAN14A
Additional proxy materials by non-management
6 Feb 20
DFAN14A
Additional proxy materials by non-management
6 Feb 20
PRER14A
Preliminary revised proxy
31 Jan 20

Other

View all
EFFECT
Notice of effectiveness
15 Sep 17
CORRESP
Correspondence with SEC
13 Sep 17
UPLOAD
Letter from SEC
12 Sep 17
EFFECT
Notice of effectiveness
3 Nov 16
CORRESP
Correspondence with SEC
2 Nov 16
CORRESP
Correspondence with SEC
28 Oct 16
UPLOAD
Letter from SEC
12 Oct 16
CORRESP
Correspondence with SEC
7 Oct 16
CORRESP
Correspondence with SEC
30 Sep 16
UPLOAD
Letter from SEC
29 Sep 16

Ownership

View all
4
ENZO BIOCHEM / FABIAN BLANK ownership change
30 Apr 20
4/A
ENZO BIOCHEM / PETER J IV CLEMENS ownership change
30 Apr 20
4
ENZO BIOCHEM / PETER J IV CLEMENS ownership change
29 Apr 20
4
ENZO BIOCHEM / Rebecca J. Fischer ownership change
29 Apr 20
4
ENZO BIOCHEM / Dov Perlysky ownership change
29 Apr 20
4/A
ENZO BIOCHEM / BARRY W WEINER ownership change
27 Feb 20
SC 13D/A
Enzo Biochem Inc
27 Feb 20
4/A
ENZO BIOCHEM / ELAZAR RABBANI ownership change
27 Feb 20
4/A
ENZO BIOCHEM / David Bench ownership change
27 Feb 20
4
ENZO BIOCHEM / David Bench ownership change
26 Feb 20

Patents

View all
APP
Utility
Sphingosine Kinase Type 1 Inhibitors and Uses Thereof
25 Jun 20
Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management.
GRANT
Utility
Methods and intermediates for synthesizing SK1-I
16 Jun 20
The invention provides methods for synthesizing the compound (2R,3S,4E)-N-methyl-5-(4′-pentylphenyl)-2-aminopent-4-ene-1,3-diol, also known as SK1-I, and intermediate compounds used in its synthesis.
GRANT
Utility
Sphingosine pathway modulating compounds for the treatment of cancers
9 Jun 20
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
GRANT
Utility
Sphingosine pathway modulating compounds for the treatment of cancers
26 May 20
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
GRANT
Utility
Sphingosine pathway modulating compounds for the treatment of cancers
12 May 20
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.